Market Access Insights
Access the relevant market access data and insights you need on health plans, policy restrictions, PBMs, providers, and more
Report
May 3, 2010
Formulary Advantages Among Hepatitis C Virus Therapies: Pharmacy directors do not yet understand the pharmacoeconomic incentives to cover emerging therapies
Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma. Increasing diagnosis and treatment rates, and substantial unmet need combine to make HCV a high-gr…
Report
March 26, 2010
Formulary Advantages in Parkinson’s Disease Drugs: Impact of Generic Entry and Novel Formulation on Reimbursement
Parkinson's disease (PD) is one of the most common neurodegenerative diseases in the elderly. The launch of several new therapies and new formulations of key brands will drive market growth, but g…
